Organon & Co. Files 8-K: Director Changes & Officer Appointments
Ticker: OGN · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1821825
| Field | Detail |
|---|---|
| Company | Organon & CO. (OGN) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.01, $1 m, $4 million, $1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, management-change, filing
TL;DR
Organon & Co. 8-K: Board shakeup and new execs announced.
AI Summary
Organon & Co. filed an 8-K on October 27, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also covers other events and financial statements/exhibits, with the earliest reported event date being October 26, 2025.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if numerous or unexpected, can indicate internal shifts that may affect company direction or stability.
Key Players & Entities
- Organon & Co. (company) — Registrant
- October 26, 2025 (date) — Earliest event reported
- October 27, 2025 (date) — Filing date
- 30 Hudson Street, Floor 33, Jersey City, NJ 07302 (address) — Principal executive offices
FAQ
Who has departed from Organon & Co.'s board or officer positions?
The filing indicates the departure of directors and certain officers, but specific names are not detailed in the provided text.
Were any new directors elected to Organon & Co.'s board?
Yes, the filing explicitly states the election of directors as an item of information.
Were there any new officer appointments at Organon & Co.?
Yes, the filing mentions the appointment of certain officers.
What is the primary business of Organon & Co. according to the filing?
Organon & Co. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on October 26, 2025.
Filing Stats: 1,893 words · 8 min read · ~6 pages · Grade level 13.9 · Accepted 2025-10-27 07:37:52
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share OGN NYSE Indicate by ch
- $1 m — Mr. Morrissey's salary was increased to $1 million, his bonus target was increased t
- $4 million — -term incentive target was increased to $4 million effective next year. In addition, he wa
- $1 million — ion, he was awarded a one-time grant of $1 million restricted stock units to be issued at
Filing Documents
- tm2529513d1_8k.htm (8-K) — 41KB
- tm2529513d1_ex99-1.htm (EX-99.1) — 15KB
- 0001104659-25-102324.txt ( ) — 227KB
- ogn-20251026.xsd (EX-101.SCH) — 3KB
- ogn-20251026_lab.xml (EX-101.LAB) — 33KB
- ogn-20251026_pre.xml (EX-101.PRE) — 22KB
- tm2529513d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On October 27, 2025, the Company issued a press release announcing the results to date of an investigation by the Audit Committee of the Board regarding the Company's wholesaler sales practices. The investigation is substantially complete, although the Company's review of its internal control over financial reporting is ongoing, as discussed below. Based on the investigation findings to date, as further described below, the Company has determined that there will be no restatement or revision to any of its previously issued financial statements. There has been no finding that the Company's Chief Financial Officer was aware of the improper wholesaler sales practices. Audit Committee Investigation After concerns regarding the Company's wholesaler sales practices for Nexplanon were brought to the Board's attention, the Audit Committee oversaw an independent, internal investigation into these sales practices. The Audit Committee's investigation has focused on the Company's sales of Nexplanon to wholesalers. The investigation has found that the Company asked certain wholesalers in the United States to purchase greater quantities of Nexplanon at the end of the fourth quarter of 2022, the third and fourth quarters of 2024 and the first, second and third quarters of 2025 (collectively, the "Relevant Periods") than they otherwise would have purchased based on wholesaler demand. In certain instances, the Company waived inventory management fee performance metrics associated with caps on days of inventory in exchange for such wholesalers accepting the Nexplanon sales, enabling the wholesalers to receive incentive fees from the Company that they otherwise would not have received. Although the incremental amount of Nexplanon sales that occurred during the Relevant Periods represented less than 1% of the Company's consolidated revenue for the year ended December 31, 2022 or December 31, 2024 as applicable (and less than 2% of the Company's consoli
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 27, 2025 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Organon & Co. By: /s/ Matthew Walsh Name: Matthew Walsh Title: Chief Financial Officer Dated: October 27, 2025